FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2116738722> ?p ?o ?g. }

• W2116738722 endingPage "151" @default.
• W2116738722 startingPage "144" @default.
• W2116738722 abstract "The major obstacle in treating ovarian cancer is the rapid development of platinum resistance during therapy. Deregulation of members of the E2F family of transcription factors is crucially involved in carcinogenesis and probably in mechanisms underlying platinum resistance. We therefore investigated the relevance of the whole set of E2F family members in predicting clinical outcome and their significance in predicting platinum resistance.Real-time PCR of all E2F family members was done from 77 ovarian carcinomas, defined as our training set, and 8 healthy control samples. The correlation with clinicopathologic characteristics, platinum resistance, and survival was investigated. Furthermore, the cross-talk of E2F family members was assessed for its value in predicting survival and platinum resistance.The proliferation-promoting E2F1 and E2F2 were associated with grade 3 tumors and residual disease >2 cm in diameter after initial surgery. Survival analyses showed low expression of E2F1 or E2F2 to be significantly associated with favorable disease-free and overall survival (E2F1, P = 0.039 and 0.047, respectively; E2F2, P = 0.009 and 0.006, respectively). In contrast, high expression of inhibiting E2F4 or E2F7 predicted favorable disease-free and overall survival (E2F4, P = 0.047 and 0.042, respectively; E2F7, P = 0.048 and 0.042, respectively). A high E2F2 to E2F4 ratio was the most valuable prognostic variable for disease-free survival in multivariate analysis (hazard ratio, 6.494; P = 0.002). Tumors considered platinum resistant were associated with lower E2F4 and E2F7 expression (P = 0.012 and 0.009, respectively) compared with platinum-sensitive tumors. Again, ratios of E2F1 or E2F2 to E2F7 were the most favorable variables in predicting platinum resistance.We here show that deregulation of both proliferation-promoting and proliferation-inhibiting E2F transcription factors and their cross-talk is crucially involved in the tumor biology of ovarian cancer and influences clinical outcome. Furthermore, down-regulation of E2F7 may contribute to mechanisms underlying platinum resistance, and calculation of ratios of proliferation-promoting E2F1 to E2F7 could serve as a putative predictor of platinum resistance." @default.
• W2116738722 created "2016-06-24" @default.
• W2116738722 creator A5004931007 @default.
• W2116738722 creator A5006608114 @default.
• W2116738722 creator A5025519748 @default.
• W2116738722 creator A5027871779 @default.
• W2116738722 creator A5034695241 @default.
• W2116738722 creator A5039758439 @default.
• W2116738722 creator A5049725450 @default.
• W2116738722 creator A5054387977 @default.
• W2116738722 creator A5061545433 @default.
• W2116738722 date "2007-01-01" @default.
• W2116738722 modified "2023-10-01" @default.
• W2116738722 title "Clinical Relevance of E2F Family Members in Ovarian Cancer—An Evaluation in a Training Set of 77 Patients" @default.
• W2116738722 cites W1964591535 @default.
• W2116738722 cites W1965223939 @default.
• W2116738722 cites W1977048390 @default.
• W2116738722 cites W1980807416 @default.
• W2116738722 cites W1991847137 @default.
• W2116738722 cites W1995979905 @default.
• W2116738722 cites W2005627404 @default.
• W2116738722 cites W2012307677 @default.
• W2116738722 cites W2020288787 @default.
• W2116738722 cites W2038768356 @default.
• W2116738722 cites W2044153456 @default.
• W2116738722 cites W2058886425 @default.
• W2116738722 cites W2059884945 @default.
• W2116738722 cites W2061349698 @default.
• W2116738722 cites W2064113174 @default.
• W2116738722 cites W2065071195 @default.
• W2116738722 cites W2065343028 @default.
• W2116738722 cites W2076213444 @default.
• W2116738722 cites W2076303985 @default.
• W2116738722 cites W2083187335 @default.
• W2116738722 cites W2086642593 @default.
• W2116738722 cites W2090258042 @default.
• W2116738722 cites W2091289547 @default.
• W2116738722 cites W2097336177 @default.
• W2116738722 cites W2104519300 @default.
• W2116738722 cites W2119958264 @default.
• W2116738722 cites W2132786809 @default.
• W2116738722 cites W2149139293 @default.
• W2116738722 cites W2169786616 @default.
• W2116738722 doi "https://doi.org/10.1158/1078-0432.ccr-06-0780" @default.
• W2116738722 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17200349" @default.
• W2116738722 hasPublicationYear "2007" @default.
• W2116738722 type Work @default.
• W2116738722 sameAs 2116738722 @default.
• W2116738722 citedByCount "101" @default.
• W2116738722 countsByYear W21167387222012 @default.
• W2116738722 countsByYear W21167387222013 @default.
• W2116738722 countsByYear W21167387222014 @default.
• W2116738722 countsByYear W21167387222015 @default.
• W2116738722 countsByYear W21167387222016 @default.
• W2116738722 countsByYear W21167387222017 @default.
• W2116738722 countsByYear W21167387222018 @default.
• W2116738722 countsByYear W21167387222019 @default.
• W2116738722 countsByYear W21167387222020 @default.
• W2116738722 countsByYear W21167387222021 @default.
• W2116738722 countsByYear W21167387222022 @default.
• W2116738722 countsByYear W21167387222023 @default.
• W2116738722 crossrefType "journal-article" @default.
• W2116738722 hasAuthorship W2116738722A5004931007 @default.
• W2116738722 hasAuthorship W2116738722A5006608114 @default.
• W2116738722 hasAuthorship W2116738722A5025519748 @default.
• W2116738722 hasAuthorship W2116738722A5027871779 @default.
• W2116738722 hasAuthorship W2116738722A5034695241 @default.
• W2116738722 hasAuthorship W2116738722A5039758439 @default.
• W2116738722 hasAuthorship W2116738722A5049725450 @default.
• W2116738722 hasAuthorship W2116738722A5054387977 @default.
• W2116738722 hasAuthorship W2116738722A5061545433 @default.
• W2116738722 hasConcept C10515644 @default.
• W2116738722 hasConcept C121608353 @default.
• W2116738722 hasConcept C126322002 @default.
• W2116738722 hasConcept C143998085 @default.
• W2116738722 hasConcept C183022183 @default.
• W2116738722 hasConcept C207103383 @default.
• W2116738722 hasConcept C2780427987 @default.
• W2116738722 hasConcept C29537977 @default.
• W2116738722 hasConcept C44249647 @default.
• W2116738722 hasConcept C502942594 @default.
• W2116738722 hasConcept C63363279 @default.
• W2116738722 hasConcept C71924100 @default.
• W2116738722 hasConcept C83258922 @default.
• W2116738722 hasConcept C86803240 @default.
• W2116738722 hasConceptScore W2116738722C10515644 @default.
• W2116738722 hasConceptScore W2116738722C121608353 @default.
• W2116738722 hasConceptScore W2116738722C126322002 @default.
• W2116738722 hasConceptScore W2116738722C143998085 @default.
• W2116738722 hasConceptScore W2116738722C183022183 @default.
• W2116738722 hasConceptScore W2116738722C207103383 @default.
• W2116738722 hasConceptScore W2116738722C2780427987 @default.
• W2116738722 hasConceptScore W2116738722C29537977 @default.
• W2116738722 hasConceptScore W2116738722C44249647 @default.
• W2116738722 hasConceptScore W2116738722C502942594 @default.
• W2116738722 hasConceptScore W2116738722C63363279 @default.
• W2116738722 hasConceptScore W2116738722C71924100 @default.
• W2116738722 hasConceptScore W2116738722C83258922 @default.

• next